Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 4/2015

01.04.2015 | Vasculitis (L Espinoza, Section Editor)

Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?

verfasst von: Ignacio García-De LaTorre, Ignacio García-Valladares

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

The appearance of biologic agents for the treatment of diverse autoimmune diseases in particular rheumatoid arthritis at the end of the 1990s changed the treatment of these patients. With the introduction of new agents in the treatment of rheumatic diseases, we started to notice the presence of new and sometimes unexpected adverse events. It is well recognized that infections are the main concern with these types of treatments; however, the occurrence of autoimmune abnormalities is also seen and its gaining perhaps more attention as the use of these agents is increasing. The first clinical trials of anti-tumor necrosis factor-α (anti-TNFα) inhibitors showed an increase of antinuclear and anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies in patients treated with these agents. In this paper, we review the frequency of these autoantibodies in patients treated with biologic agents, particularly anti-TNF-α inhibitors, and its correlation with autoimmune processes as well as the clinical relevance of such findings.
Literatur
1.
Koopman WJ. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 2008;58:S75–8.CrossRefPubMed
2.
Pernice W, Schuchmann L, Dippell J, Suschke J, Vogel P, Truckenbrodt H, et al. Therapy for systemic juvenile rheumatoid arthritis with gamma-interferon: a pilot study of nine patients. Arthritis Rheum. 1989;32:643–6.CrossRef
3.
Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1989;32:964–73.CrossRefPubMed
4.
Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704–12.CrossRefPubMed
5.
Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.CrossRefPubMed
6.
Tutuncu Z, Kavanaugh A. Anticytokine therapies. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR, editors. Kelley’s textbook of rheumatology. 9th ed. Philadelphia: Elsevier; 2013. p. 957–77.
7.••
Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73:17–23. Important study in which two groups of experts formulated 25 recommendations intended to clarify and standardize clinical and technical aspects pertaining to the determination of ANAs and related antigen-specific antibodies.CrossRefPubMed
8.
Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–11.CrossRefPubMed
9.
Lügering A, Schmidt N, Lügering M, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145–57.CrossRefPubMed
10.
Bell DA, Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin Immunol Immunopathol. 1991;60:13–26.CrossRefPubMed
11.
Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005;64:403–7.CrossRefPubMedCentralPubMed
12.
Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002;360:645.CrossRefPubMed
13.
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to antitumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381–7.CrossRefPubMed
14.
Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol. 2007;56(5 Suppl):S114–6.CrossRefPubMed
15.
Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–43.CrossRefPubMedCentralPubMed
16.
Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329–36.CrossRefPubMed
17.
Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6–14.CrossRefPubMed
18.
Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat. 2004;15(5):280–9.CrossRef
19.
Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58(1):94–105.CrossRefPubMed
20.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–63.CrossRefPubMed
21.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet. 1999;354:1932–9.CrossRefPubMed
22.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.CrossRefPubMed
23.
Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, et al. Impact of three anti- TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondyloarthropathies patients. J Clin Immunol. 2008;28:445–55.CrossRefPubMed
24.
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383–90.CrossRefPubMed
25.
Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–7.CrossRefPubMedCentralPubMed
26.••
Yukawa N, Fujii T, Kondo-Ishikawa S, et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther. 2011;13:R213. This study suggests that the ANA titer before starting infliximab in RA patients predicts the clinical response to this anti-TNF-α inhibitor. The increased titers of ANA or anti-ds-DNA antibodies after infliximab therapy may be useful markers of no response.CrossRefPubMedCentralPubMed
27.
De Rycke L, Kruithof E, Van Damme N, Hoffman IEA, Van de Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum. 2003;48(4):1015–23.CrossRefPubMed
28.
Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long term infliximab treatment. Arthritis Res Ther. 2004;6:264–72.CrossRef
29.
Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004;22:756–8.PubMed
30.
Atzeni F, Sarzi-Puttini P, Dell’Acqua D, de Portu S, Cecchini G, Cruini C, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one year prospective study. Arthritis Res Ther. 2006;8(1):R3.CrossRefPubMedCentralPubMed
31.
Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-α blockers. Clin Exp Rheumatol. 2008;26:401–7.PubMed
32.
Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91–5.CrossRefPubMed
33.••
Takase K, Horton SC, Ganesha A, Das S, McHugh A, Emery P, et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis. 2014;73:1695–9. The study demonstrates no utility of serial ANA/dsDNA testing that could be used to predict onset of seroconversion and therefore the development of lupus/vasculitis. Also it is suggested that there is an association between seroconversion and the development of a secondary non-response to bDMARD therapy.CrossRefPubMed
34.
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-α agents. Ann NY Acad Sci. 2005;1051:559–69.CrossRefPubMed
35.
Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M, on behalf of the BIOGEAS Study Group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.CrossRefPubMed
36.
De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus. 2006;15:762–7.CrossRef
37.
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–51.CrossRef
38.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
39.
De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545–51.CrossRefPubMedCentralPubMed
40.
Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716–20.CrossRef
41.
Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248–52.CrossRef
Metadaten
Titel
Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?
verfasst von
Ignacio García-De LaTorre
Ignacio García-Valladares
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 4/2015
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0500-9

Weitere Artikel der Ausgabe 4/2015

Current Rheumatology Reports 4/2015 Zur Ausgabe

Antiphospholipid Syndrome (D Erkan, Section Editor)

Pediatric Antiphospholipid Syndrome

Vasculitis (LR Espinoza, Section Editor)

Cogan’s Syndrome and Other Ocular Vasculitides

Antiphospholipid Syndrome (D Erkan, Section Editor)

Difficult Clinical Situations in the Antiphospholipid Syndrome

Orphan Diseases (B Manger, Section Editor)

Rheumatic Manifestations of Scurvy

Surgery and Perioperative Care (CR MacKenzie and SM Goodman, Section Editors)

Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery

Rheumatoid Arthritis (L Moreland, Section Editor)

Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise